ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 1998

Anika Therapeutics develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue repair. Key marketed products include AMVISC (ophthalmic surgery, manufactured for Bausch & Lomb), ORTHOVISC (human osteoarthritis, marketed internationally), and HYVISC (equine osteoarthritis). The company is developing INCERT (adhesion prevention) and OSSIGEL (bone fracture healing). In the U.S., ORTHOVISC remains investigational; the FDA rejected the initial Pre-Market Approval (PMA) in October 1998, requiring additional clinical data. An Investigational Device Exemption (IDE) for a second Phase III trial was approved in March 1999.

Key Financial Metrics (Year Ended Dec 31, 1998)

Debt & Liquidity: The company reported no long-term debt on the balance sheet. Cash flow from operating activities was $3,353,000. Capital expenditures totaled $2,238,000, primarily for manufacturing expansion. The company initiated a $4.0 million stock repurchase plan in October 1998, purchasing 359,500 shares by year-end.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 16% to $13.87 million. Product revenue rose 33.6% to $12.37 million, driven by a 220% increase in ORTHOVISC sales ($2.96 million increase) and a 4% increase in AMVISC sales.
• Licensing Fees: Decreased 44% to $1.5 million due to a $1.5 million payment from Zimmer for territory expansion in 1998, compared to $2.7 million in 1997 (which included a $2.5 million initial payment).
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 30.5% to $2.73 million due to higher consulting, recruiting, and marketing costs. R&D expenses remained flat at approximately $1.96 million.
• Profitability: Net income increased 30% to $4.35 million, aided by a significant increase in net interest income ($1.31 million vs. $0.26 million in 1997) resulting from higher cash balances following a December 1997 stock offering.

Guidance, Outlook, Risks, and Contingencies

• Regulatory Outlook: The company expects substantial R&D expense increases in 1999 due to the new Phase III clinical trial for ORTHOVISC. There is no assurance that the FDA will approve the PMA or that the trial will demonstrate efficacy.
• Manufacturing Capacity: The company expects to complete facility expansion in 1999, providing adequate capacity through 2003.
• Key Risks:
  • FDA Approval: Failure to obtain U.S. approval for ORTHOVISC would materially impact future revenue.
  • Customer Concentration: AMVISC sales to Bausch & Lomb accounted for 65% of product revenue in 1998. The supply contract expires in 2001, with no assurance of renewal or continued volume above minimums.
  • Patent Interference: A third party is attempting to provoke a patent interference regarding the INCERT product, which could jeopardize future marketing rights.
  • Stock Price Volatility: The stock price declined significantly in October 1998 following the FDA's rejection of the initial PMA.
• Liquidity: Management believes cash on hand ($22.7 million) is sufficient to fund operations for at least 24 months, though future financing may be required for new facilities or if clinical trials exceed expectations.

Investor Verification Checklist

• FDA Status: Verify the timeline and progress of the new Phase III clinical trial for ORTHOVISC and the likelihood of PMA approval.
• Bausch & Lomb Contract: Confirm the status of the AMVISC supply agreement and whether 1999 sales volumes are expected to exceed minimum purchase obligations.
• Patent Interference: Monitor the outcome of the patent interference proceeding regarding the INCERT product.
• Stock Repurchase: Track the execution of the remaining $2.0 million authorization under the stock repurchase plan.
• Capital Expenditures: Verify the completion and cost of the manufacturing facility expansion scheduled for 1999.